Differential proteomic profiling of primary and recurrent chordomas
Differential proteomic profiling of primary and recurrent chordomas
复制标题
原发性和复发性脊索瘤的差异蛋白质组学分析
DOI：
10.3892/or.2015.3818
复制
发表时间：
2015-05-01
期刊：
影响因子：
4.2
通讯作者：
Xiao, Jianru
中科院分区：
文献类型：
--
作者：
Chen, Su;Xu, Wei;Xiao, Jianru
脊索瘤是一种局部破坏性肿瘤，复发率高，预后差。涉及脉络膜复发的机制仍然很大程度上未知。在本研究中，我们研究了蛋白质组学的脉络膜原发性肿瘤（CSO）和复发性肿瘤（CSR）通过质谱在脉络膜患者谁接受手术。生物信息学分析结果表明，在CSO和CSR之间，有359个蛋白质的表达存在显著差异，21条通路发生了显著变化。CSR显示碳水化合物代谢显著增加。免疫组化（IHC）证实肿瘤干细胞标志物激活的白细胞粘附分子（ALCAM或CD 166）在复发肿瘤中的表达水平高于原发肿瘤。本研究分析了CSO和CSR之间的蛋白质组学变化，并确定了复发性脊索瘤的新生物标志物ALCAM。这一发现揭示了脉络膜复发的病理生理学，并探索更有效的预后生物标志物和针对这种毁灭性疾病的靶向治疗。
Chordomas are locally destructive tumors with high rates of recurrence and a poor prognosis. The mechanisms involved in chordoma recurrence remain largely unknown. In the present study, we examined the proteomic profile of a chordoma primary tumor (CSO) and a recurrent tumor (CSR) through mass spectrum in a chordoma patient who underwent surgery. Bioinformatic analysis of the profile showed that 359 proteins had a significant expression difference and 21 pathways had a striking alteration between the CSO and the CSR. The CSR showed a significant increase in carbohydrate metabolism. Immunohistochemistry (IHC) confirmed that the cancer stem cell marker activated leukocyte cell adhesion molecule (ALCAM or CD166) expression level was higher in the recurrent than that in the primary tumor. The present study analyzed the proteomic profile change between CSO and CSR and identified a new biomarker ALCAM in recurrent chordomas. This finding sheds light on unraveling the pathophysiology of chordoma recurrence and on exploring more effective prognostic biomarkers and targeted therapies against this devastating disease.